Literature DB >> 30497761

Novel electrocardiographic features in carriers of hypertrophic cardiomyopathy causing sarcomeric mutations.

Mikko Jalanko1, Tiina Heliö2, Pirjo Mustonen3, Jorma Kokkonen3, Heini Huhtala4, Mika Laine2, Pertti Jääskeläinen5, Mika Tarkiainen6, Kirsi Lauerma7, Petri Sipola6, Markku Laakso8, Johanna Kuusisto8, Kjell Nikus9.   

Abstract

OBJECTIVES: The sensitivity and specificity of the conventional 12-lead ECG to identify carriers of hypertrophic cardiomyopathy (HCM) - causing mutations without left ventricular hypertrophy (LVH) has been limited. We assessed the ability of novel electrocardiographic parameters to improve the detection of HCM mutation carriers.
METHODS: We studied 140 carriers (G+) of the TPM1-Asp175Asn or MYBPC3-Gln1061X pathogenic variants for HCM: The G+/LVH+ group (n = 98) consisted of mutation carriers with LVH and the G+/LVH- group (n = 42) without LVH. The control group consisted of 30 subjects. The standard 12-lead ECG was comprehensively analyzed and two novel ECG variables were introduced: RV1<RV2>RV3 and septal remodeling. A subset of 65 individuals underwent cardiac magnetic resonance imaging and 2D strain echocardiography.
RESULTS: Conventional major ECG criteria were sensitive (90%) and specific (97%) in identifying G+/LVH+ subjects. RV1<RV2>RV3 and septal remodeling were more prevalent in the G+/LVH- subjects compared to the control group (33% vs 3%, p = 0.005 and 45% vs 3%, p < 0.001, respectively). The combination of RV1<RV2>RV3 and Q waves and repolarization abnormalities (QR) differentiated between the G+/LVH- subjects and the control group with a sensitivity of 52% and specificity of 97%. The combination of septal remodeling and QR differentiated between G+/LVH- subjects and the control group with a sensitivity of 64% and specificity of 97%.
CONCLUSIONS: The novel ECG-parameters RV1<RV2>RV3 and septal remodeling were effective in identifying G+/LVH- subjects and could be useful in the diagnostics of new suspected HCM patients and in the screening and follow-up of HCM families.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Electrocardiography; Hypertrophic cardiomyopathy; Mutation carrier

Mesh:

Substances:

Year:  2018        PMID: 30497761     DOI: 10.1016/j.jelectrocard.2018.07.009

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  2 in total

1.  Distinct Metabolomic Signatures in Preclinical and Obstructive Hypertrophic Cardiomyopathy.

Authors:  Maike Schuldt; Beau van Driel; Sila Algül; Rahana Y Parbhudayal; Daniela Q C M Barge-Schaapveld; Ahmet Güçlü; Mark Jansen; Michelle Michels; Annette F Baas; Mark A van de Wiel; Max Nieuwdorp; Evgeni Levin; Tjeerd Germans; Judith J M Jans; Jolanda van der Velden
Journal:  Cells       Date:  2021-10-29       Impact factor: 6.600

2.  Clinical Data, Chest Radiograph and Electrocardiography in the Screening for Left Ventricular Hypertrophy: The CAR2E2 Score.

Authors:  Patrycja S Matusik; Amira Bryll; Agnieszka Pac; Tadeusz J Popiela; Paweł T Matusik
Journal:  J Clin Med       Date:  2022-06-22       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.